Entering text into the input field will update the search result below

Aurinia extends losses as analysts cut price targets after Q4 results

Mar. 02, 2022 1:10 PM ETAurinia Pharmaceuticals Inc. (AUPH)By: Dulan Lokuwithana, SA News Editor25 Comments

Wall street sign in New York with New York Stock Exchange background

naphtalina/iStock via Getty Images

The commercial-stage biotech, Aurinia Pharmaceuticals (AUPH -4.7%), is trading lower for the third straight session on Wednesday to reach a seven-month low after several Wall Street analysts trimmed their price targets on the stock

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.